Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Income: 2010-2025

Historic Net Income for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Sep 2025 value amounting to -$22.6 million.

  • Vanda Pharmaceuticals' Net Income fell 324.23% to -$22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.2 million, marking a year-over-year decrease of 413.85%. This contributed to the annual value of -$18.9 million for FY2024, which is 853.29% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Net Income is -$22.6 million, which was up 16.92% from -$27.2 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Net Income registered a high of $9.6 million during Q2 2021, and its lowest value of -$29.5 million during Q1 2025.
  • Its 3-year average for Net Income is -$8.7 million, with a median of -$4.5 million in 2024.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Net Income spiked by 1,856.46% in 2021 and then plummeted by 3,057.78% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' Net Income (Quarterly) stood at $7.1 million in 2021, then decreased by 2.96% to $6.9 million in 2022, then tumbled by 134.71% to -$2.4 million in 2023, then crashed by 105.44% to -$4.9 million in 2024, then plummeted by 324.23% to -$22.6 million in 2025.
  • Its Net Income was -$22.6 million in Q3 2025, compared to -$27.2 million in Q2 2025 and -$29.5 million in Q1 2025.